» Articles » PMID: 24763403

Sin3a-associated Hdac1 and Hdac2 Are Essential for Hematopoietic Stem Cell Homeostasis and Contribute Differentially to Hematopoiesis

Overview
Journal Haematologica
Specialty Hematology
Date 2014 Apr 26
PMID 24763403
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Class I histone deacetylases are critical regulators of gene transcription by erasing lysine acetylation. Targeting histone deacetylases using relative non-specific small molecule inhibitors is of major interest in the treatment of cancer, neurological disorders and acquired immune deficiency syndrome. Harnessing the therapeutic potential of histone deacetylase inhibitors requires full knowledge of individual histone deacetylases in vivo. As hematologic malignancies show increased sensitivity towards histone deacetylase inhibitors we targeted deletion of class I Hdac1 and Hdac2 to hematopoietic cell lineages. Here, we show that Hdac1 and Hdac2 together control hematopoietic stem cell homeostasis, in a cell-autonomous fashion. Simultaneous loss of Hdac1 and Hdac2 resulted in loss of hematopoietic stem cells and consequently bone marrow failure. Bone-marrow-specific deletion of Sin3a, a major Hdac1/2 co-repressor, phenocopied loss of Hdac1 and Hdac2 indicating that Sin3a-associated HDAC1/2-activity is essential for hematopoietic stem cell homeostasis. Although Hdac1 and Hdac2 show compensatory and overlapping functions in hematopoiesis, mice expressing mono-allelic Hdac1 or Hdac2 revealed that Hdac1 and Hdac2 contribute differently to the development of specific hematopoietic lineages.

Citing Articles

Construction and evaluation of liposomal drug delivery system for an ALK/HDACs dual-targeted inhibitor with sustained release and enhanced antitumor effect.

Ren F, Gan Z, Zhang Q, He D, Chen B, Wu X Drug Deliv Transl Res. 2024; 15(3):939-954.

PMID: 39112826 DOI: 10.1007/s13346-024-01647-1.


Nucleoporin Nup358 drives the differentiation of myeloid-biased multipotent progenitors by modulating HDAC3 nuclear translocation.

Guglielmi V, Lam D, DAngelo M Sci Adv. 2024; 10(23):eadn8963.

PMID: 38838144 PMC: 11152124. DOI: 10.1126/sciadv.adn8963.


Emerging Roles of Epigenetic Regulators in Maintaining Hematopoietic Stem Cell Homeostasis.

Wang H, Han Y, Qian P Adv Exp Med Biol. 2024; 1442:29-44.

PMID: 38228957 DOI: 10.1007/978-981-99-7471-9_3.


Epigenetic Mechanisms in Hematologic Aging and Premalignant Conditions.

Yan B, Yuan Q, Guryanova O Epigenomes. 2023; 7(4).

PMID: 38131904 PMC: 10743085. DOI: 10.3390/epigenomes7040032.


Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis.

Wallace L, Obeng E Front Mol Biosci. 2023; 10:1273046.

PMID: 38028538 PMC: 10644717. DOI: 10.3389/fmolb.2023.1273046.


References
1.
Yamaguchi T, Cubizolles F, Zhang Y, Reichert N, Kohler H, Seiser C . Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 2010; 24(5):455-69. PMC: 2827841. DOI: 10.1101/gad.552310. View

2.
Shimazu T, Hirschey M, Newman J, He W, Shirakawa K, Le Moan N . Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2012; 339(6116):211-4. PMC: 3735349. DOI: 10.1126/science.1227166. View

3.
Heideman M, Wilting R, Yanover E, Velds A, de Jong J, Kerkhoven R . Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood. 2013; 121(11):2038-50. PMC: 3596963. DOI: 10.1182/blood-2012-08-450916. View

4.
Haggarty S, Tsai L . Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol Learn Mem. 2011; 96(1):41-52. PMC: 3188418. DOI: 10.1016/j.nlm.2011.04.009. View

5.
Miharada K, Karlsson G, Rehn M, Rorby E, Siva K, Cammenga J . Hematopoietic stem cells are regulated by Cripto, as an intermediary of HIF-1α in the hypoxic bone marrow niche. Ann N Y Acad Sci. 2012; 1266:55-62. DOI: 10.1111/j.1749-6632.2012.06564.x. View